Jump to content

Main Page: Difference between revisions

From Neoplasm
← Older edit
VisualWikitext
No edit summary
%login% (talk | contribs)
37 edits
m Replaced content with "%About_Yourself%"
Tags: Replaced Manual revert
 
(100 intermediate revisions by 62 users not shown)
Line 1: Line 1:
{{DISPLAYTITLE:}}
%About_Yourself%
__NOTOC__
<!-- Hides title of Main Page via CSS (see PART B) -->
 
<div class="neoplasm-center">
  <div class="neoplasm-hero-title">Neoplasm.org <small>- An Open Hematology/Oncology Reference</small></div>
</div>
 
<div class="neoplasm-center neoplasm-hero-subtitle">
Neoplasm.org is a collaborative, open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens.
Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.
 
{| class="wikitable neoplasm-table neoplasm-table--quicklinks"
|-
| colspan="2" class="neoplasm-table-title" | Quick links to major topic areas
|-
| class="neoplasm-chip neoplasm-chip--solid"    | [[#solidtumors|Solid Tumors]]
| class="neoplasm-chip neoplasm-chip--malignant" | [[#malignantheme|Malignant Hematology]]
|}
 
==Links to all main disease pages==
<span id="solidtumors"></span>
 
{| class="wikitable neoplasm-table neoplasm-table--grid"
|-
! colspan="4" class="neoplasm-major neoplasm-major--solid" | '''Solid Tumors'''
|-
| colspan="4" class="neoplasm-minor neoplasm-minor--solid" | '''Breast Oncology'''
|-
| colspan="4" class="neoplasm-sub" | '''Early breast cancer (EBC)'''
|-
| class="neoplasm-cell" | [[Early breast cancer|EBC, NOS]]
| class="neoplasm-cell" | [[Early breast cancer, HR-positive|HR-positive EBC]]
| class="neoplasm-cell" | [[Early breast cancer, HER2-positive|HER2-positive EBC]]
| class="neoplasm-cell" | [[Early breast cancer, HER2-low|HER2-low EBC]]
|-
| class="neoplasm-cell" | [[Early breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive EBC]]
| class="neoplasm-cell" | [[Early breast cancer, triple negative|Early triple-negative breast cancer (eTNBC)]]
|-
| colspan="4" class="neoplasm-sub" | '''Metastatic breast cancer (MBC)'''
|-
| class="neoplasm-cell" | [[Metastatic breast cancer|MBC, NOS]]
| class="neoplasm-cell" | [[Metastatic breast cancer, HR-positive|HR-positive MBC]]
| class="neoplasm-cell" | [[Metastatic breast cancer, HER2-positive|HER2-positive MBC]]
| class="neoplasm-cell" | [[Metastatic breast cancer, HER2-low|HER2-low MBC]]
|-
| class="neoplasm-cell" | [[Metastatic breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive MBC]]
| class="neoplasm-cell" | [[Metastatic breast cancer, triple negative|Metastatic triple-negative breast cancer (mTNBC)]]
| class="neoplasm-cell" | [[Breast cancer, CNS metastases|CNS metastases]]
|-
| colspan="4" class="neoplasm-sub" | '''Breast cancer with molecular alterations'''
|-
| class="neoplasm-cell" | [[Breast cancer, BRCA-mutated|BRCA-mutated Breast cancer]]
| class="neoplasm-cell" | [[Metastatic breast cancer, PI3K pathway-altered|PI3K pathway-altered Breast cancer]]
|-
| colspan="4" class="neoplasm-minor neoplasm-minor--solid" | '''Dermatologic Oncology'''
|-
| colspan="4" class="neoplasm-sub" | '''Melanoma'''
|-
| class="neoplasm-cell" | [[Melanoma|Melanoma, NOS]]
| class="neoplasm-cell" | [[Melanoma,_BRAF-mutated|BRAF-mutated Melanoma]]
| class="neoplasm-cell" | [[Melanoma,_KIT-mutated|KIT-mutated Melanoma]]
| class="neoplasm-cell" | [[Melanoma,_NRAS-mutated|NRAS-mutated Melanoma]]
|-
| class="neoplasm-cell" | [[Uveal melanoma]]
|-
| colspan="4" class="neoplasm-sub" | '''Non-melanoma skin cancer (NMSC)'''
|-
| class="neoplasm-cell" | [[Cutaneous basal cell carcinoma|Cutaneous BCC]]
| class="neoplasm-cell" | [[Cutaneous squamous cell carcinoma|Cutaneous SCC]]
| class="neoplasm-cell" | [[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]]
|-
| colspan="4" class="neoplasm-minor neoplasm-minor--solid" | '''Endocrine Oncology'''
|-
| colspan="4" class="neoplasm-sub" | '''Other endocrine cancers'''
|-
| class="neoplasm-cell" | [[Adrenocortical carcinoma]]
| class="neoplasm-cell" | [[Neuroendocrine tumor|Neuroendocrine tumor (NET)]]
| class="neoplasm-cell" | [[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]]
| class="neoplasm-cell" | [[Pancreatic NET]]
|-
| class="neoplasm-cell" | [[Pheochromocytoma]]
|-
| colspan="4" class="neoplasm-sub" | '''Thyroid cancer without molecular alterations'''
|-
| class="neoplasm-cell" | [[Thyroid cancer|Thyroid cancer, NOS]]
| class="neoplasm-cell" | [[Thyroid cancer, anaplastic|Anaplastic thyroid cancer (ATC)]]
| class="neoplasm-cell" | [[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]]
| class="neoplasm-cell" | [[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]]
|-
| colspan="4" class="neoplasm-sub" | '''Thyroid cancer with molecular alterations'''
|-
| class="neoplasm-cell" | [[Thyroid_cancer,_BRAF-mutated|BRAF-mutated Thyroid cancer]]
| class="neoplasm-cell" | [[Thyroid_cancer,_RET-positive|RET-positive Thyroid cancer]]
|-
| colspan="4" class="neoplasm-minor neoplasm-minor--solid" | '''Gastrointestinal Oncology'''
|-
| colspan="4" class="neoplasm-sub" | '''Upper GI tract'''
|-
| class="neoplasm-cell neoplasm-cell--w25" | [[Esophageal cancer|Esophageal cancer, NOS]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Esophageal adenocarcinoma]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Esophageal squamous cell carcinoma|Esophageal squamous cell carcinoma (ESCC)]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Gastric cancer|Gastric cancer, NOS]]
|-
| class="neoplasm-cell neoplasm-cell--w25" | [[Gastric cancer, HER2-positive|HER2-positive gastric cancer]]
|-
| colspan="4" class="neoplasm-sub" | '''Lower GI tract'''
|-
| class="neoplasm-cell neoplasm-cell--w25" | [[Anal cancer]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Appendiceal tumor]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Colon cancer|Colon cancer, NOS]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Colon cancer, RAS wild-type|RAS wild-type colon cancer]]
|-
| class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer|Colorectal cancer (CRC), NOS]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer, BRAF-mutated|BRAF-mutated CRC]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer, HER2-positive|HER2-positive CRC]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer, MSI-H or dMMR|MSI-H or dMMR CRC]]
|-
| class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer, RAS wild-type|RAS wild-type CRC]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Rectal cancer]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Small bowel adenocarcinoma]]
|-
| colspan="4" class="neoplasm-sub" | '''Hepatobiliary cancer'''
|-
| class="neoplasm-cell neoplasm-cell--w25" | [[Biliary tract cancer]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Cholangiocarcinoma]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Gallbladder cancer]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]]
|-
| class="neoplasm-cell neoplasm-cell--w25" | [[Periampullary adenocarcinoma]]
|-
| colspan="4" class="neoplasm-sub" | '''Pancreatic cancer'''
|-
| class="neoplasm-cell neoplasm-cell--w25" | [[Pancreatic cancer|Pancreatic adenocarcinoma, NOS]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Pancreatic cancer, BRCA-mutated|BRCA-mutated Pancreatic adenocarcinoma]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Pancreatic cancer, NRG1-positive|NRG1-positive Pancreatic adenocarcinoma]]
| class="neoplasm-cell neoplasm-cell--w25" | [[Pancreatic NET]]
|-
|}
 
<span id="malignantheme"></span>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#cf0001"| '''Malignant Hematology'''
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Acute leukemias'''
|-
|style="width: 25%; background-color:#fee0d2"|[[Acute leukemia, KMT2A-rearranged]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, FLT3-positive | AML, FLT3-positive]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, IDH-mutated | AML, IDH-mutated]]
|-
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, NPM1-mutated | AML, NPM1-mutated]]
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]]
|-
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]]
|style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]]
|style="background-color:#fee0d2"|[[CNS leukemia]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
|-
|style="background-color:#fee0d2"|[[Chronic myeloid leukemia | Chronic myeloid leukemia (CML)]]
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
|-
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis (PMF/SMF)]]
|style="background-color:#fee0d2"|[[Myeloproliferative neoplasm, accelerated phase|Myeloproliferative neoplasm, accelerated phase (MPN-AP)]] <span style="color: red"><small>New</small></span>
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
|-
|style="background-color:#fee0d2"|[[Systemic mastocytosis]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Aggressive lymphomas'''
|-
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
|style="background-color:#fee0d2"|[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]
|style="background-color:#fee0d2"|[[CNS lymphoma]]
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
|-
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma, gastric|Gastric DLBCL]] <span style="color: red"><small>New</small></span>
|style="background-color:#fee0d2"|[[High-grade B-cell lymphoma|High-grade B-cell lymphoma (HGBL)]]
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]]
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
|-
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Indolent lymphomas'''
|-
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia| Chronic lymphocytic leukemia (CLL/SLL)]]
|style="background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
|style="background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
|style="background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
|-
|style="background-color:#fee0d2"|[[Indolent lymphoma|Indolent lymphoma (iNHL)]]
|style="background-color:#fee0d2"|[[B-cell lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]]
|style="background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
|style="background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Plasma cell dyscrasias'''
|-
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (main page)]]
|style="background-color:#fee0d2"|[[Multiple_myeloma,_induction|MM,]] induction
|style="background-color:#fee0d2"|[[Multiple_myeloma,_consolidation_and_maintenance|MM, consolidation &]] maintenance
|-
|style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]]
|style="background-color:#fee0d2"|[[Plasma cell leukemia|Plasma cell leukemia (PCL)]]
|style="background-color:#fee0d2"|[[POEMS syndrome]]
|style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''T-cell and NK-cell neoplasms'''
|-
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
|style="background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
|style="background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
|style="background-color:#fee0d2"|[[Extranodal NK- and T-cell lymphoma, nasal type|Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT]]
|-
|style="background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
|style="background-color:#fee0d2"|[[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]]
|style="background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic lymphoma (T-LBL)]]
|-
|style="background-color:#fee0d2"|[[T-cell prolymphocytic leukemia | T-cell prolymphocytic lymphoma (T-PLL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Lymphoproliferative disorders'''
|-
|colspan="2" style="background-color:#fee0d2"|[[Castleman disease]]
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocytic disorders'''
|-
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]]
|style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]]
|style="background-color:#fee0d2"|[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]]
|style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Disease-agnostic'''
|-
|style="background-color:#fee0d2"|[[Malignant hematologic neoplasm, FGFR1-mutated|FGFR1]] <span style="color: red"><small>New</small></span>
|-
|}
 
<div class="neoplasm-center neoplasm-footer-link">'''[[Special:AllPages|Browse our complete index of pages]]'''</div>
 
==Additional Information==
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes [[how to contribute|continuous peer review]].
 
Any information that one feels would be helpful to other oncology providers is welcome. Visit [[how to contribute]] for more details.
 
Priorities of this project include:
<section begin=goals />
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature.
*'''[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
<section end=goals />
 
Additional possibilities for this project may include:
*Creating synopses of pivotal clinical trials and regimens
*Prioritizing regimens by their efficacy and/or toxicity
*Capturing historical regimens that were standard-of-care prior to 2005
*Checklists for common clinical scenarios/diseases
*Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
 
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [https://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
 
<br><inputbox>
type=create
width=70
placeholder=Type the name of the page you want to create
break=no
</inputbox>

Latest revision as of 06:20, 16 October 2026

%About_Yourself%

Retrieved from "https://neoplasm.org/index.php?title=Main_Page&oldid=592009"